Introduction
the development, manufacture and sale of medicinal products are activities regulated by law. As part of the process to release medicinal products on the market, a marketing authorisation must be granted by a competent regulatory authority. this authorisation is issued on the basis of an assessment of a submitted dossier of the particular medicinal product, including information relating to the administrative, manufacturing, preclinical and clinical data.
After having been granted a marketing authorisation, the marketing authorisation holder is obliged, in case of a change in any part of the dossier, to notify/submit an application variation form to the regulatory authorities and to follow the procedures pursuant to the national or/and european legislation.
Variations in the terms of marketing authorisations are an imperative process ensuring quality, efficacy and safety of the medicinal products which reach the patients. irrespective of whether they relate to administrative changes or changes in the manufacturing process or to any safety issues, these are subject to strict control by the regulatory authorities.
this article aims to analyse the evolution of the regulatory conditions and requirements for the variations to the terms of marketing authorisations for medicinal products, based on the submitted variations applications in Bulgaria over the period after the accession to the european Union on 1 January 2007. A chronology analysis of the regulatory documents in the field of variations for the period from 1995 until the introduction of the recent commission Regulation (ec) no 1234/2008 (11) in Bulgaria in February 2011 was also performed.
Materials and Methods

Documentary method
Several legislative documents in the variation field in the eU context and in Bulgaria for the period 1995-2011 were reviewed and analysed. 
Comparative analysis
Historical analysis
The data from the period from 2007 to 2010 in the fields of variation of the MAs for Bulgaria was covered in this article.
Empirical method
Sources from different annual reports of the Bulgarian Drug Agency (BDA) were compared and extrapolated. to facilitate the implementation of european Union (eU) standards and good practices, the european commission set up CADREAC (Collaboration Agreement Process) and the Pan European Regulatory Forum (PERF) in 1997 and in 1999, respectively, for the regulators in the eU and candidate countries. the aims were to bridge the regulatory gap between east and west and promote a good scientific and regulatory practice by identifying practical arrangements for the implementation of the eU pharmaceutical legislation.
REGULATORY ANALYSIS OF THE VARIATION PROCEDURES OF MEDICINAL PRODUCTS AFTER THE EU
the eU enlargement had a massive impact on many areas, including pharmaceuticals. The influence of CADREAC and PERF resulted in a new Bulgarian pharmaceutical legislation in 2000 and in 2002, respectively. the Bulgarian variation legislation was also affected by these changes. Major revisions for harmonisation in line with eU pharmaceutical directives (14) were adopted in February 2000 and December 2002. Several topics from the eU legislation were introduced and others were amended to comply with the internationally accepted pharmaceutical standards in the eU (3, 18). (Fig. 1) .
An increasing trend was observed to the number of (Fig. 2) . For the procedures on the decentralised principle (MRP and DCP) in 2010 there is a decrease of 3.6 % in the total number of submitted variation applications versus 2009 (Fig. 2) , and this is obviously a consequence of the introduction of the new rules of commission Regulation (ec) no 1234/2008 and the possibility for grouping and annual reporting of the Type ІА variations (13, 19, 22) .
in Bulgaria, the requirements relating to commission Regulation (ec) no 1234/2008 (11) are transposed into the national legislation, but the "worksharing" procedures were not included and purely national procedures could not be switched to the European MRPs without "repeat use procedure". For the "worksharing" procedure after an amendment of commission Regulation (ec) no 1234/2008 (11) with commission Regulation (eU) no 712/2012 Annex Vi there is an exception for Bulgaria to switch the already national authorised products to MRP renewal or variations and in Germany, where that exception will be valid until the implementation in the national legislation 2013 (12, 13, 15, 16, 17, 19, 22 ).
Positive outcomes and issues which need development in the variation field in the EU and in Bulgaria as well
• According to commission Regulation (ec) no 1234/2008 there is no option for a uniform submission of an electronic dossier (еCTD) and, in case of grouping, a separate ectD shall be prepared for the life cycle management of each product.
• Grouping is possible with a single application, which saves paper work and is great advantage for the regulatory authorities and the MAhs, where the resources, time and administrative burden could be optimised, which would lead to a more flexible and less time-consuming work process (2).
• harmonisation of the Bulgarian legislation with the European norms in the field of variations in MA of medicinal products as of February 2011 does not include the "worksharing" procedure, which could also be serious advantage to switch the already national authorised products to MRP renewal or variations.
• Fee payments for grouping and for annual report variations in the eU regulatory authority (eMA) have no incentives and each separate procedure in the group is being paid in Bulgaria as well.
• Post-marketing variations of medicinal products represent the most serious administrative burden for the regulatory authorities and the industry. the following simplification and alleviation according to Commission Regulation (ec) no 1234/2008 were implemented: -"Do and tell" changes for type iA procedures which make the work easier and flexible for the MAH and regulatory authorities; -The 12-month period of notification for Type IA variations after implementation is great advantage in Bulgaria, where the variation procedures type iA till February 2011 required mandatory approval, which was repealed upon the eU rules after that time; -opportunity for grouping various types of variations ensures exceptional flexibility for MAHs as well as different strategies in the submission of applications and saving financial resources and workload;
-Variations type "iB by default" are option to classify variations which are unknown till the submission date and will be in the prerogatives of the regulatory authority or the coordination Group cMD(h), which is a serious challenge where variation could not be classified.
• establishment of a system for following up the implementation of type iA variations is necessary to introduce an auxiliary control system by both MAhs and regulatory authorities.
• After the amendment of ordinance 27 in June 2011
there is direct reference in Art. 15d to the Variation classification of the Commission Guidelines (2010/C 17/01) only and the classification is no longer part of the Regulation and placed on the regulatory body website like a guideline. this led to a rapid and easiest update in the harmonisation with the european regulatory norms and best practices.
Conclusions
the "Worksharing" procedure, which has not been adopted in the Bulgarian legislation, could provide an option to include the national procedures in the Mutual Recognition Procedure without carrying out "repeat use", which would save a great deal of effort and funds to the regulatory authorities and the MAhs by the additional implementation of a "repeat use" procedure. the grouping problem for any variation will be the necessity of updating the ectD form of any dossier, since there is no complex approach introduced in the eU for grouped submission to the regulatory authority. Due to the complex character of this problem, this direction should be perfected in the future and an it complex approach needs to be established to electronic dossiers for variations.
the Bulgarian legislation needs to follow the best practices in some eU member states where some variations are free or with reduced fees when they are grouped in order to save time and resources to the pharmaceutical industry.
the regulatory environment in Bulgaria by the end of June 2011 was in the process of implementing the new provision of Chapter III, Section VI of LMPHM, applied to the updated Moh ordinance 27 in June 2011, which covers the updated approach in variations for the national procedures. the experience of separate guideline variation classification was also implemented in Bulgaria in 2011 as a reference to the eU Guideline included in ordinance 27 which provide easy opportunity for regular update (15) . the implementation of commission Regulation (ec) no 1234/2008 in Bulgaria is associated with various challenges in view of the numerous innovations and the range of guidelines which the Coordination Group СМD(h) and ЕМА regularly introduce and update.
